Home LiteratureArticle Details
PMID: 3235657 Published · ppublish English Journal Article

Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing.

Journal of clinical microbiology ·Vol. 26 ·No. 11 ·1988-11-00 ·Pages 2307-12

Guinet R, Nerson D, de Closets F, Dupouy-Camet J, Kures L, Marjollet M, Poirot JL, Ros A, Texier-Maugein J, Volle PJ

Abstract

The new micromethod for yeast susceptibility testing, MYCOTOTAL, was evaluated with 10 reference strains in seven laboratories. Ready-to-use microtitration plates and the same synthetic medium were used with two dilutions of imidazoles, flucytosine, and amphotericin B, permitting the categorization of each strain as susceptible, intermediate, or resistant. The results were compared with the MIC for each reference strain, and the repeatability and reproducibility were evaluated. The yeasts tested presenting different patterns of susceptibilities in reference MICs included six strains of Candida albicans, two strains of Candida tropicalis, one strain of Candida parapsilosis, and one strain of Torulopsis glabrata. For 4,200 antifungal agent-yeast results, the repeatability was 99.3% and the reproducibility was 96.3%. The correlation between the reference MICs and the category results was 91.5% for seven laboratories (and 92.7% for six laboratories excluding the laboratory which did not follow exactly the same protocol). We observed only 7.9% minor discrepancies, 0.5% (0.29% for six laboratories) major discrepancies, and 0.1% uninterpretable results. The percentages of concording results were similar for each strain and each antifungal agent tested. The overall results indicated that MYCOTOTAL was a reliable and reproducible method, well correlated with reference MICs. This ready-to-use micromethod with the same medium for all antifungal agents would be an important step in the necessary standardization of yeast susceptibility testing.

MeSH Terms
Antifungal Agents/pharmacology Candida/drug effects Laboratories/standards Microbial Sensitivity Tests/standards Quality Control Species Specificity
Chemicals
Antifungal Agents
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Guinet R
Centre d'Immunochimie Microbienne, Institut Pasteur, Domaine du Poirier, Lentilly, L'Arbresle, France.
Nerson D
de Closets F
Dupouy-Camet J
Kures L
Marjollet M
Poirot J L
Ros A
Texier-Maugein J
Volle P J
References (32)
32 references, click to expand
  1. New azole compounds: vibunazole (Bay n7133) and Bay L9139, compared with ketoconazole in the therapy of systemic candidosis and in pharmacokinetic studies, in mice.
    J Antimicrob Chemother. 1985 Jan;15(1):69-75 PMID: 3972759
  2. Antifungal drug susceptibility testing. A critical review.
    Mycopathologia. 1984 Sep 30;87(3):135-40 PMID: 6392886
  3. Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole.
    J Clin Microbiol. 1986 Aug;24(2):269-71 PMID: 3528213
  4. Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions.
    J Med Vet Mycol. 1986 Aug;24(4):305-11 PMID: 3746584
  5. Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro.
    J Antimicrob Chemother. 1986 Oct;18(4):473-8 PMID: 3021710
  6. Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts.
    J Clin Microbiol. 1986 Oct;24(4):507-11 PMID: 3533974
  7. [Comparative sensitivity of yeasts to antifungal agents using a standardized micromethod].
    Pathol Biol (Paris). 1986 May;34(5):536-9 PMID: 3534739
  8. Preliminary studies on the pharmacology and therapeutic activity of oral and intravenous econazole.
    Mykosen Suppl. 1978;1:192-201 PMID: 299476
  9. Test methods for antifungal agents--a critical review.
    Mykosen. 1987 Jan;30(1):28-37 PMID: 3550458
  10. In vitro antifungal susceptibility testing and measurement of levels of antifungal agents in body fluids.
    Rev Infect Dis. 1987 Mar-Apr;9(2):392-7 PMID: 3296103
  11. Prevention and mycoses in immunocompromised patients.
    Rev Infect Dis. 1987 Mar-Apr;9(2):408-16 PMID: 3296106
  12. [Multicenter study of the standardization of sensitivity testing of fungi to 5-fluorocytosine and amphotericin B].
    Mykosen. 1987 Jul;30(7):306-8, 311-4 PMID: 3657853
  13. Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies.
    Antimicrob Agents Chemother. 1972 Dec;2(6):423-6 PMID: 4677595
  14. Laboratory evaluation of a rapid, automatic susceptibility testing system: report of a collaborative study.
    Antimicrob Agents Chemother. 1975 Apr;7(4):466-80 PMID: 1147582
  15. Miconazole-resistant Candida.
    Lancet. 1978 Jan 7;1(8054):50-1 PMID: 74535
  16. Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative.
    Antimicrob Agents Chemother. 1979 Apr;15(4):597-602 PMID: 464592
  17. The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole.
    J Antimicrob Chemother. 1980 Jan;6(1):97-104 PMID: 6244258
  18. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections.
    Drugs. 1980 Jan;19(1):7-30 PMID: 6988200
  19. Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance.
    J Antimicrob Chemother. 1980 Nov;6(6):749-61 PMID: 7440468
  20. An evaluation of two years of clinical experience with ketoconazole.
    Rev Infect Dis. 1980 Jul-Aug;2(4):674-87 PMID: 6255549
  21. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.
    Drugs. 1982 Jan-Feb;23(1-2):1-36 PMID: 6276122
  22. Disposition of ketoconazole, an oral antifungal, in humans.
    Antimicrob Agents Chemother. 1982 Jan;21(1):151-8 PMID: 6282204
  23. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice.
    Chemotherapy. 1982;28(6):461-79 PMID: 6297858
  24. Antifungal agents used in systemic mycoses. Activity and therapeutic use.
    Drugs. 1983 Jan;25(1):41-62 PMID: 6297871
  25. Ketoconazole therapy for fungal urinary tract infections.
    J Urol. 1983 Jan;129(1):68-70 PMID: 6298476
  26. Fatal septicemia due to amphotericin B-resistant Candida lusitaniae.
    J Clin Microbiol. 1983 Aug;18(2):443-4 PMID: 6619295
  27. Relative inhibition factors--a novel approach to the assessment of antifungal antibiotics in vitro.
    J Antimicrob Chemother. 1984 Jan;13(1):31-43 PMID: 6698909
  28. Azole resistance in Candida albicans.
    Sabouraudia. 1984;22(1):53-63 PMID: 6322363
  29. Ketoconazole in the prevention of experimental candidal vaginitis.
    Antimicrob Agents Chemother. 1984 Feb;25(2):281-2 PMID: 6324671
  30. In-vitro resistance to imidazole antifungals in Candida albicans.
    J Antimicrob Chemother. 1984 Jun;13(6):547-58 PMID: 6381460
  31. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents.
    J Antimicrob Chemother. 1984 Aug;14(2):105-14 PMID: 6094418
  32. Correlation of susceptibility test results in vitro with response in vivo: ketoconazole therapy in a systemic candidiasis model.
    Chemotherapy. 1985;31(5):395-404 PMID: 3902391
Article Info
Journal
Journal of clinical microbiology
Abbr.
J Clin Microbiol
ISSN
0095-1137
Published
1988-11-00
Pages
2307-12
Language
English
Region
United States
NLM ID
7505564
PMCID
PMC266882
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com